New combo therapy targets hard-to-treat lymphoma
NCT ID NCT04827862
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 19 times
Summary
This study tests whether adding low-dose radiation to the immunotherapy drug pembrolizumab can help people with relapsed or refractory non-Hodgkin lymphoma. Six adults with at least two measurable tumor sites are receiving the combination. The goal is to see how many patients achieve complete remission, and how long the benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abamson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.